The primary objective of this protocol is to evaluate [18F]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical. The specific objectives are:~To measure the dynamic uptake and washout of [18F]MNI-1054 in brain using positron emission tomography (PET) in healthy volunteers.~To measure blood metabolites of [18F]MNI-1054 in the healthy volunteers and to perform invasive as well as non-invasive modeling to assess its ability to measure LSD1 in the brain.~To acquire safety data following injection of [18F]MNI-1054~Evaluation of [18F]MNI-1054 PET reliability (test/retest) of the tracer parameters in healthy volunteers.
The primary objective of this protocol is to evaluate [18F]MNI-1054 as a Lysine-specific histone demethylase 1A (LSD1) enzyme targeted radiopharmaceutical.